The FDA has approved datopotamab deruxtecan (Dato-DXd, Datroway, Daiichi Sankyo) for the treatment of patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy. The approval marks the second breast cancer indication in the US for the Trop-2-directed antibody and topoisomerase inhibitor conjugate…
Read More
Datopotamab Deruxtecan Earns New Breast Cancer Indication
